Results 111 to 120 of about 3,487 (207)

Exploring Comorbidities in MOGAD: A scoping review

Myelin Oligodendrocyte Glycoprotein antibody-associated disease (MOGAD) is an inflammatory demyelinating disorder of the central nervous system. Although the symptoms of MOGAD overlap with those of other demyelinating conditions such as multiple ...
Gabriela Blaszczyk, Mahir Rahman, Ruth Ann Marrie, Doriana Taccardi   +3 more
core  

A narrative review of the economic burden of myelin oligodendrocyte glycoprotein antibody-associated disease and analogous conditions

Frontiers in Neurology
BackgroundMyelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) is an inflammatory demyelinating disease of the central nervous system with a serious, debilitating presentation, including residual disability after relapses.ObjectivesTo ...
Leonard Lee, Joshua Byrnes, Cathryn Hope, Hansoo Kim   +3 more
doaj   +1 more source

Protocol - modelling predictors for relapsing disease in MOGAD

In myelin oligodendrocyte glycoprotein antibody associated disease (MOGAD), only approximately 40%-60% of patients develop a relapsing disease course, for which the preventative treatment is long-term immunotherapy.

core   +1 more source

Reduced tolerogenic factor sCD83 in NMOSD and relapsing MOGAD: a potential new therapeutic pathway

Frontiers in Immunology
BackgroundNeuromyelitis optica spectrum disorders (NMOSD) and myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) are autoimmune central nervous system disorders with poorly understood immune pathways. CD83 plays a crucial role in the
Ariel Rechtman, Ariel Rechtman, Omri Zveik, Omri Zveik, Lyne Shweiki, Lyne Shweiki, Garrick Hoichman, Garrick Hoichman, Garrick Hoichman, Tal Friedman-Korn, Tal Friedman-Korn, Livnat Brill, Livnat Brill, Adi Vaknin-Dembinsky, Adi Vaknin-Dembinsky   +14 more
doaj   +1 more source

NMOSD and MOGAD Dual Positivity

Annals of Indian Academy of Neurology, 2022
Ayush Agarwal, Aminu Aliyar, Shilpa Rao, Anita Mahadevan, Ajay Garg, Achal Srivastava   +5 more
openaire   +3 more sources

Assessing the applicability of the 2023 international MOGAD panel criteria in real-world clinical settings

<jats:title>Abstract</jats:title><jats:sec> <jats:title>Introduction</jats:title> <jats:p>Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) is a recently identified
Zveik, Omri, Hoichman, Garrick, Shweiki, Lyne, Rechtman, Ariel, Freidman-Korn, Tal, Vaknin-Dembinsky, Adi   +5 more
core   +1 more source

MOGAD and Mortality: A Rarity

Annals of Indian Academy of Neurology
UK Kandha Kumar, Pradeep K Gunasekaran, Ashna Kumar, Daisy Khera, Sarbesh Tiwari, Lokesh Saini   +5 more
openaire   +3 more sources

Extra Orbital Manifestations of MOGAD

, 2020
MOGAD(myelin oligodendrocyte associated disorder) is an inflammatory demyelinating condition of the CNS characterized by a monophasic or relapsing course of neurological dysfunction.
Lakshmi Leishangthem; Shannon Beres; Heather Moss
core  

Efficacy and safety of interleukin-6 receptor inhibitors in myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD): A systematic review and meta-analysis. [PDF]

Ther Adv Neurol Disord
Ali A, Shahid A, Iqbal J, Ansari AU, Rauf M, Sarfraz S, Amjad A, Masood HMY, Ali MA, Saleem U, Shabbir MA, Shabbir MT, Abdullah A, Sharma MK.   +13 more
europepmc   +1 more source

Clinical Prognostic Factors Associated With Relapsing Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease: A Multicenter Cohort Study. [PDF]

Neurol Neuroimmunol Neuroinflamm
Human M, Gilmartin CGS, Papathanasiou A, Tench CR, Siriratnam P, Rocchi C, Gran B, Hargovan M, The EZ, Varley JA, Huda S, Tanasescu R.   +11 more
europepmc   +1 more source